Targeting uPA-uPAR interaction to improve intestinal epithelial barrier integrity in inflammatory bowel disease - eBioMedicine

uPAR Antibody AF807 from R&D Systems, a Bio-Techne Brand

TRIM40 is a pathogenic driver of inflammatory bowel disease subverting intestinal barrier integrity. - Abstract - Europe PMC

Intestinal Barrier Dysfunction in Inflammatory Bowel Disease: Underpinning Pathogenesis and Therapeutics

Full article: Recent progress in plant-derived polysaccharides with prebiotic potential for intestinal health by targeting gut microbiota: a review

Frontiers Role of glycolysis in inflammatory bowel disease and its associated colorectal cancer

uPAR, beyond regulating physiological functions, has orchestrated roles in cancer (Review)

Extracellular vesicles-mediated interaction within intestinal microenvironment in inflammatory bowel disease. - Abstract - Europe PMC

PDF) Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer

Intestinal Barrier Dysfunction in Inflammatory Bowel Disease: Underpinning Pathogenesis and Therapeutics

Pathologically catalyzed physical coating restores the intestinal barrier for inflammatory bowel disease therapy, Journal of Nanobiotechnology

Targeting uPA-uPAR interaction to improve intestinal epithelial barrier integrity in inflammatory bowel disease - eBioMedicine

Frontiers Yishen Qingli Heluo Granule Ameliorates Renal Dysfunction in 5/6 Nephrectomized Rats by Targeting Gut Microbiota and Intestinal Barrier Integrity

Mechanisms of Intestinal Epithelial Barrier Dysfunction by Adherent-Invasive Escherichia coli - ScienceDirect

Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice

James Garnett's research works